Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06609 心瑋醫療-B
Listing Date2021/08/20
Listing Price171.000
  • 100.300 -0.900 (-0.889%)    Sink Below Listing Price
  • 15-min delayed, last update: 21/10/2021 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    200 lot
  • One Lot Success Rate

Shanghai HeartCare Medical Technology is an innovative neuro-interventional medical device company. Its product portfolio includes both neuro-interventional and cardiac medical devices. It strives to reduce the mortality rate and improve prognosis of stroke in China and worldwide through the commercialization of our product candidates.

The Group two Core Products are CaptorTM thrombectomy device (Captor), which is for acute ischemic stroke and has been commercialized in China, and left atrial appendage (LAA) occluder, which is for atrial fibrillation and is in NMPA registration review. It has a broad portfolio of four commercialized products and 19 product candidates covering all major stroke subtypes and surgical pathways in the neuro-interventional field.

The Group had commercialized four ischemic stroke treatment devices forming a complete product suite for stent retrieving thrombectomy procedures. It commenced sales for the thrombectomy device, the distal access catheter and microcatheter in the product suite in 2020 and for our balloon guiding catheter in April 2021. Additionally, it expects to commercialize nine product candidates in 2021 and commercialize another 10 product candidates between 2022 and 2025, including the global-first1 sirolimus intracranial drugeluting balloon catheter for intracranial stenosis treatment.

All of sales revenue was sourced from distributors. As of March 31, 2021, the Group had 41 distributors covering 1135 hospitals across over 25 provinces in China.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot50
No. of Offer Shares6.60M H shares
No. of International Offer Shares5.94M H shares
No. of HK Offer Shares0.66M H shares
Offer Price$160.00 - $171.00
Stock Code6609
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited, Goldman Sachs (Asia) L.L.C.
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, Futu Securities International (Hong Kong) Limited, Goldman Sachs (Asia) L.L.C.
Application PeriodAug 10 (Tue) - noon, Aug 13 (Fri)
Price Determination DateAug 13 (Fri)
Result Announcement DateOn or Before Aug 19 (Thu)
Result Announcement DateOn or Before Aug 19 (Thu)
Dealings in Shares commence onAug 20, 2021. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$160.00 - $171.00
Capitalization (H Shares)5.05B - 5.40B
NAV / share ($)$43.94 - $45.7 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 165.5, the net proceeds raised would be HKD 981.00M, of which
45.3% : allocate to Core Products;
39.9% : allocate to other product candidates;
4.8% : fund improvements to R&D capacities and expansion of product portfolio; and
10% : additional working capital
Code Name Nominal Change %Change
02500VENUS MEDTECH-Bdown40.650-0.700-1.693%
15-min delayed, last updated: 21/10/2021 17:59
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.